Ideal Potassium Level Before ARR Testing
Serum potassium should be normalized to at least 4.0 mmol/L (ideally ≥4.0 mmol/L) before performing the aldosterone-renin ratio test. 1, 2
Why Potassium Correction Matters
Hypokalemia is a potent inhibitor of aldosterone secretion and will cause false-negative results on ARR testing 1, 3. This physiologic suppression occurs because low potassium directly reduces aldosterone production from the adrenal glands, masking the autonomous aldosterone secretion characteristic of primary aldosteronism.
Specific Correction Protocol
- Target level: Serum potassium ≥4.0 mmol/L 1, 2
- Correction method: Use potassium chloride (KCl) supplementation 2
- Critical caveat: Avoid potassium supplements containing or generating potassium bicarbonate, as these are less effective for this purpose 2
When to Retest After Initial Negative Screen
If the initial ARR screen is negative but hypokalemia was present, repeat the test on a different day after correcting the potassium 1. This is particularly important in patients with:
- Moderate to high pretest probability for primary aldosteronism
- Resistant hypertension
- Suppressed renin with borderline aldosterone levels (5-10 ng/dL by immunoassay)
Additional Testing Considerations
Beyond potassium correction, the 2025 Endocrine Society guidelines emphasize 1:
- Morning blood draw after being awake >2 hours
- 5-15 minutes in seated position before collection
- Unrestricted salt intake (minimum 5 g/day NaCl) 2
- Proper blood collection technique using syringe and needle (avoid fist clenching, wait ≥5 seconds after tourniquet release)
Clinical Context
While older studies suggested various potassium thresholds (some as low as 3.2 mmol/L for screening purposes 4), the most recent 2025 guidelines are explicit that normalization to ≥4.0 mmol/L is required before testing 1, 2. This higher threshold reflects our understanding that even mild hypokalemia can suppress aldosterone secretion enough to produce false-negative results, potentially missing cases of primary aldosteronism that require treatment to reduce cardiovascular morbidity and mortality.